PGT-A or Untested Embryos: Which Fits?

One of the hardest moments in IVF is realizing there is no universally “right” answer. When patients ask about PGT-A or untested embryos, what they are usually asking is something deeper: Which option gives me the best chance of a healthy pregnancy without adding stress I do not need?

That is a fair question, and it deserves a careful answer. PGT-A can be very helpful in some cases, but it is not automatically the best choice for every patient, every cycle, or every embryo. Untested embryos can still lead to healthy pregnancies and healthy babies. The best decision depends on your age, embryo development, medical history, and what matters most to you emotionally and practically.

How to think about PGT-A or untested embryos

PGT-A stands for preimplantation genetic testing for aneuploidy. In simple terms, it checks whether an embryo appears to have the expected number of chromosomes. The goal is to identify embryos that are more likely to implant and less likely to result in miscarriage due to chromosomal abnormalities.

An untested embryo is exactly what it sounds like - an embryo that has not gone through this screening step. It may still be chromosomally normal, or it may not. Without testing, doctors choose embryos for transfer based on factors such as development stage and visual grading rather than chromosomal information.

This is why the decision is rarely just about technology. It is about how much information you want before transfer, how many embryos you have available, and how you want to balance time, uncertainty, and treatment intensity.

What PGT-A may help with

For the right patient, PGT-A can add clarity. If several embryos reach the blastocyst stage, testing may help identify which embryos are most likely to lead to a successful transfer. That can reduce some of the guesswork in deciding transfer order.

PGT-A may also be worth discussing if you have had recurrent miscarriage, repeated failed transfers, or if maternal age is a major factor. As egg age increases, the chance of chromosomal abnormalities rises as well. In that setting, genetic testing may help avoid transferring embryos that are unlikely to result in an ongoing pregnancy.

Some patients also choose PGT-A because they want more information before moving forward. IVF can feel emotionally heavy, and for some families, having an additional layer of data brings peace of mind. It does not remove uncertainty, but it can make the process feel more guided.

That said, PGT-A is a screening tool, not a guarantee. A euploid embryo, meaning one that tested normal, can still fail to implant. A tested embryo is not a promise of pregnancy. It is one piece of the clinical picture.

When untested embryos may still make sense

Untested embryos remain a very reasonable choice in many IVF journeys. If you have only a small number of embryos, the value of testing may be less clear. Some patients prefer to move directly to transfer rather than add another laboratory step.

This can be especially true for younger patients with a favorable prognosis, or for those who produce only one or two embryos. In these situations, your care team may feel that transfer based on embryo quality is an appropriate path.

There is also a practical reality that matters. Not every embryo will continue developing after biopsy and freezing, even in excellent labs, although modern techniques have improved outcomes significantly. For some patients, especially those with limited embryo numbers, preserving every opportunity for transfer feels more important than gathering more data first.

Emotion matters here too. Some intended parents do not want to make decisions based on genetic screening if the testing is unlikely to change their transfer plan. Others feel more comfortable giving each embryo a chance through transfer rather than selection through testing. That perspective is personal, and it deserves respect.

The biggest factors that shape the decision

Age is one of the most common reasons PGT-A enters the conversation. As maternal age rises, the percentage of embryos with chromosomal abnormalities tends to increase. In those cases, testing may help identify embryos with higher implantation potential and lower miscarriage risk.

But age alone should not make the decision for you. The number of embryos available matters just as much. If you have multiple blastocysts, PGT-A may help prioritize them. If you have only one embryo, the question becomes more nuanced. Testing may provide information, but it may not change what happens next if that embryo would be transferred either way.

Your reproductive history also matters. If you have experienced repeated IVF failure or recurrent pregnancy loss, your doctor may be more likely to recommend testing as part of a broader strategy. If this is your first IVF cycle and you have a strong prognosis, transferring untested embryos may be entirely appropriate.

Then there are your personal goals. Some patients want the fastest route to transfer. Others want as much information as possible before making decisions. Neither approach is wrong. The right plan is the one that aligns medical reasoning with your values.

What patients often misunderstand about PGT-A

One common misunderstanding is that PGT-A improves all IVF outcomes for all patients. That is not how it works. It can improve embryo selection, but its benefit varies depending on the situation.

Another misunderstanding is that untested embryos are low quality or second best. They are not. Many healthy pregnancies begin with untested embryos. A beautiful blastocyst that has not been screened may still be completely normal.

It is also easy to assume that PGT-A gives black-and-white answers. In reality, embryo biology is more complex than that. Some results are clearly normal or clearly abnormal, while others may fall into more complicated categories. This is why good counseling matters. Test results need to be interpreted in the context of the whole case, not in isolation.

Why this decision should be individualized

The most supportive fertility care does not push every patient toward the same protocol. It explains the pros, the limits, and the trade-offs clearly enough that you can make a decision with confidence.

For some patients, PGT-A makes the path feel more efficient and focused. For others, transferring untested embryos is the more balanced choice. A thoughtful clinic will not oversimplify that difference. It will review your ovarian reserve, age, fertilization outcomes, blastocyst development, previous pregnancies, and emotional priorities before recommending a plan.

That level of personalization matters even more for patients traveling for care. If you are coordinating treatment internationally, you want a strategy that feels medically sound and logistically realistic. In a high-touch setting like Dr. Alex Aldape’s fertility care in Mexico, these decisions can be discussed in detail before your cycle starts, so you understand not only what is recommended, but why.

Questions worth asking before you decide on PGT-A or untested embryos

A good consultation should leave you with more clarity, not more confusion. Ask how many embryos are expected to reach blastocyst, whether testing is likely to change your transfer strategy, and how your age and history affect the recommendation.

You should also ask what the clinic sees in patients like you. Not in general terms, but in cases with your ovarian response, your diagnosis, and your goals. The most useful answer is rarely absolute. It is usually something like, “In your case, here is where testing may help, and here is where it may not.”

That kind of honesty builds trust. It also helps reduce the pressure to make a decision based on fear.

The better question is not which option is best

The better question is which option fits your situation best right now. If PGT-A would meaningfully guide embryo selection and support your treatment plan, it may be a strong choice. If untested embryos allow you to move forward in a way that is medically reasonable and emotionally manageable, that may be the better path.

Fertility treatment is rarely about finding perfect certainty. It is about making informed decisions with a team that sees both the science and the person behind it. When that happens, even difficult choices start to feel more manageable.

If you are weighing PGT-A or untested embryos, give yourself permission to slow the conversation down and ask for a recommendation tailored to you. The right next step should feel clear, supported, and grounded in your real chances - not someone else’s story.